CASI Pharmaceuticals, Inc. (CASI) Form 6-K — Jun 2, 2026
CASI Pharmaceuticals announced that Dr. Barbara Krebs-Pohl has resigned as a director, effective May 31, 2026. The filing states the resignation was not due to any disagreement with the company. Dr.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.